

PRESS RELEASE

Indoco to conduct Early Detection of Oral Cancer Campaigns across India

Mumbai, July 26, 2017: Oral Cancer is the most common form of cancer and almost 50% cancer cases are detected in the Head and Neck region. Around 80% cases are diagnosed in the advance stage, which makes it all the more difficult to treat. Oral Cancer is the No.1 cause for death amongst all types of cancers in India. It appears as a growth or sore in the mouth that does not go away. It includes cancers of the lips, tongue, cheeks, floor of the mouth, hard and soft palate, sinuses and pharynx (throat) & can be life threatening, if not diagnosed and treated early.

Indoco Remedies Limited., a research oriented Pharma Company in Mumbai, rolled out their 'Early Detection of Oral Cancer Campaign' on the occasion of World Head & Neck Cancer Day on 27th July, 2017. Dr. Prashant Pawar, Senior Consultant Head & Neck Onco-Surgeon at Fortis Hospital addressed the gathering on the importance of early detection of Oral Cancer and its prevention.

If oral cancer is detected early (stage 1 & 2), the cure rate is nearly 90%. However, if detected at later stages (stage 3 & 4) survival rate reduces significantly (30%-40%), despite best treatment. The greatest outcome for oral cancer is always when diagnosed early –not only in terms of survival, but also in terms of functional rehabilitation”, **said Dr. Prashant Pawar, Senior Consultant Head & Neck Onco-Surgeon Fortis Hospital.**

In order to increase awareness for early detection of oral cancer, Indoco Remedies, through its division, Warren, is conducting special seminars for medical practitioners. Further, these medical practitioners will actively work for early detection of oral cancer and counsel patients detected with precancerous lesions. Various towns have been identified with large population suffering from this deadly disease for conducting these activities. Patient education information has also been developed for self-detection of oral cancer, which will be communicated to the masses through various media channels. “Indoco is committed to create awareness among patients, institutions and the medical fraternity & efforts will be made on various platforms for early detection of oral cancer” **said Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited.**

About Indoco :

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 165 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 4,65,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include, Febrex Plus, Cyclopam, Oxipod, Sensodent-K, Cital, ATM, Cloben-G, Karvol Plus, Sensoform, Sensodent-KF, Glychek-M, Carmicide, Bactoguard, Tuspel Plus, Methycal, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details, visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com

Samir Daini

Mobile: 9820301130

E-mail: samir@indoco.com